Serina Therapeutics, a leader in polymer-based drug development, today announced the appointment of Dr. Joshua Thomas as Vice President and Head of Chemistry. This strategic addition strengthens Serina’s leadership team as the company advances its proprietary polymer technology platform toward clinical-stage development.

Dr. Thomas brings extensive expertise in medicinal chemistry, polymer science, and drug delivery, with experience spanning small-molecule design, conjugation chemistry, and formulation strategies. He has held leadership roles in both pharmaceutical and biotechnology organizations, supporting preclinical and clinical development programs across diverse therapeutic areas.

In his new role, Dr. Thomas will oversee chemistry strategy across Serina’s pipeline, including the optimization of polymer-drug conjugates, scale-up activities, and integration of chemistry efforts with biology, pharmacology, and manufacturing teams. He will play a central role in advancing Serina’s lead programs, including candidates targeting neurological and other chronic diseases where sustained and targeted drug delivery may offer therapeutic benefits.

“Expanding our leadership team with a seasoned scientist like Dr. Thomas reflects our continued progress in translating our polymer-based platform into clinical-stage assets,” said [CEO/Spokesperson Name], CEO of Serina Therapeutics. “His expertise will be invaluable as we accelerate development timelines while upholding the highest scientific and manufacturing standards.”

This appointment aligns with Serina’s broader strategy to advance multiple therapeutic programs efficiently and reinforces the company’s commitment to innovation in targeted, sustained drug delivery.